

XPH

State Street SPDR S&P Pharmaceuticals ETF

Analyst Report

This ETF is one of several options for investors looking to establish exposure to the U.S. pharmaceutical industry, a sub-sector of the health care space that can post big returns during periods of consolidation or as a result of advancements in medicine. Given this narrow focus, XPH probably doesn't belong in a long-term portfolio, though it may be useful for covering a corner of the domestic equity market that receives minimal weight in most portfolios. XPH is noteworthy because of the methodology employed by the underlying index; as an equal-weighted benchmark, this fund offers balanced exposure to the pharma sector, avoiding the potential pitfalls of cap-weighted benchmarks. This equal-weighted methodology distinguishes XPH from other pharma ETFs, such as PJP, PPH, and IHE.

ESG Themes and Scores

4.91/10

ESG Rate

15.16%

Global Percentile

9.64%

Peer Percentile

Performance Data

	XPH	ETF Database Category Average	Factset Segment Average
1 Month	17.13%	13.40%	14.02%
3 Month	22.85%	17.38%	16.98%
YTD Return	20.16%	14.33%	18.89%
1 Year Return	63.92%	40.81%	54.83%
3 Year Return	19.28%	10.24%	18.64%
5 Year Return	6.36%	1.71%	9.36%

Top 5 Holdings

Symbol	Holding	% Assets
DFTX	Definium Therapeutics, Inc.	2.89%
MBX	MBX Biosciences, Inc.	2.80%
MANE	Veradermics, Incorporated	2.14%
AMLX	Amylyx Pharmaceuticals, Inc.	2.07%
ALMS	Alumis Inc.	2.06%

Vitals

Issuer	State Street
Brand	SPDR
Structure	ETF
Expense Ratio	0.35%
Inception	Jun 19, 2006
Index Tracked	S&P Pharmaceuticals Select Industry Index

ETF Database Themes

Category	Health & Biotech Equities
Asset Class	Equity
Asset Class Size	Multi-Cap
Asset Class Style	Blend
Region (General)	North America
Region (Specific)	U.S.

FactSet Classifications

Segment	Equity: U.S. Pharmaceuticals
Category	Sector
Focus	Health Care
Niche	Pharmaceuticals
Strategy	Equal
Weighting	Equal

